Introduction {#s1}
============

Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE), involving up to two thirds of patients at onset or during disease course ([@B1]--[@B3]). The inflammatory process in the kidney is driven by both cellular and humoral abnormalities, in particular formation of immune complexes ([@B4]--[@B6]).

Pentraxin3 (PTX3) belongs to the long pentraxin family, i.e., a superfamily of multimeric evolutionary conserved molecules which are released locally at sites of inflammation ([@B7]--[@B12]) and are involved in tissue homeostasis, with prominent antimicrobial functions and fine-tuning of inflammation ([@B8]--[@B10]). It has been proposed as a bridge between innate and adaptive immunity, being endowed with antibody-like properties i.e., the capability to provide opsonization of foreign or apoptotic bodies ([@B9]), to modulate antigen presentation and inflammatory responses. Indeed, soluble PTX3 exerts an anti-inflammatory function by sequestering C1q, while when bound to apoptotic debris PTX3 allows C1q fixation and subsequent enhanced activation of the classical complement pathway ([@B8], [@B10], [@B13]).

Lupus kidney is a source of autoantigens ([@B14], [@B15]), and current evidence supports PTX3 involvement in SLE-driven renal inflammation. Deposits of PTX3 have been characterized in renal samples of several immune-mediated kidney diseases including LN ([@B16]--[@B18]), where the extent of deposition correlated with proteinuria and renal fibrosis ([@B11], [@B17], [@B18]).

Moreover, clinical observations showed that SLE patients display high frequencies and titers of anti-PTX3 antibodies ([@B18]--[@B20]), which are inversely correlated with LN occurrence ([@B18], [@B19], [@B21]). Furthermore, PTX3 immunization of lupus-prone mice resulted in anti-PTX3 antibody occurrence and was associated with delayed and milder lupus-like nephritis and increased overall and disease-free survival ([@B22]), thus providing evidence for an immunomodulatory capacity of anti-PTX3 antibodies.

Despite the interaction of PTX3 with diverse cell types has been described ([@B9], [@B13], [@B23]), its relationship with B cells remains blurry. Recently, PTX3 released by specialized neutrophils was described to interact with marginal zone (MZ) B cell thereby promoting class-switch from IgM to IgG antibodies ([@B24]), however a direct interaction was not described.

In light of the aforementioned observations and open questions, and considering the established role of B cells in LN development ([@B25]), it is attractive to speculate that PTX3-specific (PTX3^+^) B cells could bear a regulatory potential in lupus and particularly in LN. Herein, we sought to develop a new method that allows identification and characterization of peripheral PTX3^+^ B cells. Using this methodology, we found PTX3^+^ B cells in SLE patients and healthy donors (HD) which were virtually absent in LN patients. This data suggests that these autoantigen specific B cells may represent a layer of regulation that is lost in LN patients.

Patients and Methods {#s2}
====================

Thirty-eight consecutive SLE patients (American College of Rheumatology criteria), including 12 with biopsy-proven LN, and 22 HD were recruited.

Active LN was defined as proteinuria \> 0.5 g/day or creatinine clearance \< 60 ml/min/1.73 m^2^, evaluated with Cockcroft and Gault formula, with active urinary sediment ([@B3]). Accordingly, LN was considered active in 7/12 patients. Demographics of all groups and clinical and therapeutic features of patients are given in Table [1](#T1){ref-type="table"}.

###### 

Demographic and therapeutic features of healthy donors and patient groups.

                                                            **Healthy donors**   **Patients**                             
  --------------------------------------------------------- -------------------- ---------------------------------------- ----------------------
  No.                                                       22                   26                                       12
  Mean age ± SD                                             33.4 ± 8.6           34.6 ± 10.2                              41.8 ± 10.37
  Female (%)                                                77.2                 84.6                                     75
  Active disease (cSLEDAI≥2) (%)                                                 3/26 (11.5%)                             7/12 (58.3%)
  cSLEDAI \[mean ± SD\]                                                          1.14 ± 3.66                              4.17 ± 3.86
  **LN class[^\*^](#TN1){ref-type="table-fn"}** **(no.)**                                                                 
      Proliferative (III or IV)                                                  N/A[^\*\*^](#TN2){ref-type="table-fn"}   7
      V or mixed                                                                                                          5
  24-h proteinuria (g) \[mean ± SD\]                                             N/A                                      4 ± 1.41
  Active urinary sediment^§^ (%)                                                 0                                        41.7
  **CONCOMITANT TREATMENT**                                                                                               
  Oral prednisone (%) \[mean daily dosage ± SD\]                                 60.8 \[4.04 ± 4.14\]                     58.3 \[3.98 ± 6.05\]
  HCQ (%)                                                                        69.4                                     58.3
  Immunosuppressants (%)                                                         73.9                                     66.7
      MMF                                                                        34.7                                     41.7
      MTX                                                                        4.3                                      0
      AZA                                                                        30.4                                     25

International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003.

*These patients never underwent kidney biopsy due to lack of renal involvement. § \> 5 white blood cells and/or \>5 red blood cells/high power field and/or heme-granular/red cell casts. SLE, systemic lupus erythematosus; LN, lupus nephritis; SD, standard deviation; cSLEDAI, clinical SLE disease activity index; HCQ, hydroxychloroquine; MMF, mycophenolate mofetil; MTX, methotrexate; AZA, azathioprine; N/A, not available*.

All subjects gave written informed consent, in accordance with the local ethics committee of the Charité Universitätsmedizin Berlin.

Whole Blood Lysis
-----------------

Blood was obtained before any induction therapy for LN in EDTA vacutainer tubes (BD Biosciences, San Jose, CA, USA) and lysed according to the manufacturer\'s instructions. Briefly, 1 ml of EDTA blood was incubated with 10 ml of lysing solution (Lysing Buffer BD Pharm Lyse™). The obtained cells were washed three times with phosphate-buffered saline/bovine serum albumin (PBS/BSA) (Miltenyi, Germany).

Staining Procedure and Flow Cytometry
-------------------------------------

To identify PTX3^+^ B cells, recombinant human purified PTX3 ([@B10]) was labeled with either cyanine 5 (Cy5) or phycoerythrin (PE). Tetanus (TT) staining was performed in parallel as control as previously described ([@B24]) in order to establish an optical reference range for PTX3^+^ cells. Antigens were labeled at the German Rheumatism Research Centre (DRFZ), Berlin.

For flow cytometric analysis, the following fluorochrome-labeled antibodies were used: PTX3 staining: anti-CD19 Allophycocyanin (APC)-Cy7 (clone SJ25C1, BioLegend), anti-CD20 Brilliant Violet (BV)510 (clone 2H7, BioLegend), anti-CD27 Fluorescein isothiocynate (FITC) (clone M-T271, BD), IgG PECy7 (clone G18-145, BD), IgD Peridinin-Chlorophyll-protein (PerCp) Cy5.5 (clone IA6-2, BD), anti-CD3/anti-CD14 Pacific Blue (PacB) (clone UCHT1/M5E2, BD). TT staining: anti-CD19 PECy7 (clone SJ25C1, BD), anti-CD20 BV510 (clone 2H7, BioLegend), anti-CD27-FITC, IgD PerCp Cy5.5 (clone IA6-2, BD), anti-CD3/anti-CD14 PacB (clone UCHT1/M5E2, BD), anti-CD38 APC-Cy7 (clone HIT2, BioLegend).

PTX3^+^B cells were identified as B cells binding both PTX3-PE and PTX3-Cy5 (Figure [1](#F1){ref-type="fig"}).

![Identification of PTX3+ B cells among CD19+CD20+ B cells. **(A)** Three representative dot plots of the PTX3-specific B cells before and after blocking with unlabeled PTX3. Only B cells staining positive for both PTX3-Cy5 and PTX3-PE were considered (light gray square). **(B)** Quantification of PTX3 binding among B cells before and after blocking of PTX3. Cy5, cyanin 5; PE, phycoerythrin. ^\*\*^ \< 0.01.](fimmu-10-00029-g0001){#F1}

TT-specific B cells were identified by the binding of TT-Cy5. Specificity of this binding was checked in parallel stainings performed in our laboratory.

After Fc receptor blocking (Miltenyi Biotec, Germany), stainings were performed in the dark at 4°C for 15 min, followed by two washing steps with PBS/BSA and centrifugation for 5 min at 4°C and 330 × g. Stained cells were analyzed by flow cytometry using a FACS Canto II flow cytometer (BD, USA).

B cell subsets were defined as naïve (single CD3^−^CD14^−^Dapi^−^CD19^+^CD20^+^CD27^−^), memory (single CD3^−^CD14^−^Dapi^−^CD19^+^CD20^+^CD27^+^) and plasmablasts (single CD3^−^CD14^−^Dapi^−^CD19^+^CD27^hi^CD20^−^).

The gating strategy is exemplarily shown in Supplementary Figure [1](#SM1){ref-type="supplementary-material"}. Absolute numbers of B subpopulations were calculated by using the absolute number of B cells/μl retrieved with Multitest 6-color TBNK analysis (BD, USA) according to the manufacturer\'s protocol.

Data Analysis and Statistics
----------------------------

Samples included in analyses had at least 1 × 10^6^ events with a minimum threshold for CD19^+^ cells of 50,000 events.

Flow cytometric data was analyzed by FlowJo software 7.6.5 (TreeStar, Ashland, OR, USA). GraphPad Prism Version 5 (GraphPad software, San Diego, CA, USA) was used for statistical analysis. To test for significance, non-parametric tests were used.

Results {#s3}
=======

Identification of PTX3^+^ B Cells in Peripheral Blood of Patients and Controls
------------------------------------------------------------------------------

Initially, we developed a flow cytometric method to identify and quantify PTX3^+^ B cells in human peripheral blood. B cells (CD3^−^CD14^−^CD19^+^CD20^+^) able to bind simultaneously PTX3-Cy5 and PTX3-PE were considered specific (Figure [1A](#F1){ref-type="fig"}) (gated as shown in Supplementary Figure [1](#SM1){ref-type="supplementary-material"}). The specificity of PTX3 binding was further confirmed by blocking with unlabeled PTX3 prior to staining (Figures [1A,B](#F1){ref-type="fig"}). Blocking of single positive PE or Cy5-PTX3 B cells could not be efficiently performed (Supplementary Figure [2](#SM2){ref-type="supplementary-material"}), thus these cells were not included in the present analysis.

PTX3^+^B Cells Are Decreased in LN Patients vs. SLE and HD
----------------------------------------------------------

LN patients showed the lowest absolute numbers of PTX3^+^ B cells among total peripheral B cells, which were also significantly decreased in comparison with HD and non-renal SLE \[mean ± standard deviation (SD) cells/ml: LN 0.023 ± 0.027 vs. HD 33.09 ± 48.15, *p* = 0.008; LN 0.023 ± 0.027 vs. non-renal SLE 12.53 ± 20.24, *p* = 0.033\] (Figure [2A](#F2){ref-type="fig"}, left).

![PTX3^+^ B cells are decreased in patients with lupus nephritis and are mainly confined to CD27^−^IgD^+^ B cells. **(A)** Absolute numbers of PTX3^+^ B cells (cell/mL) within (left) total; (middle) naïve or (right) memory B cells in HD (*n* = 22) and SLE (*n* = 26) and LN (*n* = 12) patients. **(B)** Frequencies of PTX3^+^ B cells (left), naïve (middle), and memory (right) are decreased in LN (*n* = 12) in comparison with HD (*n* = 22) and SLE (*n* = 26). **(C)** Distribution of CD27 and IgD expression by PTX3^+^ B cell subsets are shown. Enrichment in the naïve pool with decreases in the other subsets was found in HD (*n* = 22) and SLE (*n* = 26), but not in LN (*n* = 12). **(D)** Pie charts of percentages of PTX3^+^ CD27IgD subsets within the PTX3^+^ B cell pool are consistent with distribution of absolute numbers. Mann-Whitney *U*-test (^\*^ \< 0.05, ^\*\*^ \< 0.01, ^\*\*\*^ \< 0.001). SLE, systemic lupus erythematosus; HD, healthy donors; LN, lupus nephritis; PTX3 pentraxin3.](fimmu-10-00029-g0002){#F2}

Analyses of B cell subsets confirmed a substantial decrease in absolute numbers of both naïve (CD20^+^CD27^−^) and memory (CD20^+^CD27^+^) PTX3^+^ B cells in LN compared to HD and non-renal SLE patients (mean ± SD naïve/ml: LN 0.18 ± 0.58 vs. HD 30.12 ± 42.96, *p* = 0.0001; LN SLE 0.18 ± 0.58 vs. non-renal 16.22 ± 24.88, *p* = 0.028; mean ± SD memory/ml: LN 0.97 ± 2.18 vs. HD 12.75 ± 24.88, *p* = 0.011; LN 0.97 ± 2.18 vs. non-renal SLE 4.07 ± 5.21, *p* = 0.038) (Figure [2A](#F2){ref-type="fig"}, middle and right).

Moreover, the frequencies of PTX3^+^ B cells and B cell subsets were decreased in LN (Figure [2B](#F2){ref-type="fig"}), while there was no significant difference between HD and non-renal SLE.

Of note, no difference in PTX3^+^ naïve and memory compartment was identified between active and inactive LN (data not shown), suggesting that the actual decrease in LN is not related to disease activity, rather mirroring a characteristic of LN.

We detected nearly no circulating PTX3^+^ plasmablasts (CD27^hi^CD20^−/low^) in whole blood sampled for the majority of donors, where a minimum of 1 × 10^6^ events was retrieved from each sample. These cells were absent even when a larger amount of cellular events (27 × 10^6^) from an SLE patient among a total of 7,648 plasmablasts was analyzed.

Circulating PTX3^+^ B Cells Reside Mainly Within Naïve (CD20^+^CD27^−^IgD^+^) B Cells With a Similar Distribution Among HD and Non-renal SLE Patients
-----------------------------------------------------------------------------------------------------------------------------------------------------

Using CD27 and IgD as surface markers, we further subdivided B cell subpopulations. We found that the majority of circulating PTX3^+^B cells resided among the CD20^+^CD27^−^IgD^+^ mature pre-switch naïve subset, followed by a lower number of CD20^+^CD27^+^IgD^+^ B cells (Figures [2C,D](#F2){ref-type="fig"}), likely representing pre-switched memory B cells whose origin is still debated ([@B26]). This distribution remained consistent among HD and non-renal SLE patients (Figure [2C](#F2){ref-type="fig"}, left and middle), while LN patients did not show any difference among B cell subsets (Figure [2C](#F2){ref-type="fig"}, right). Proportions of PTX3^+^ CD27IgD B cell subsets in relationship to the whole PTX3^+^ B cell pool are shown in Figure [2D](#F2){ref-type="fig"}.

Discussion {#s4}
==========

In this study, we aimed at characterizing the distribution of an PTX3^+^ B cells in peripheral blood of SLE patients, focusing on potential differences between LN and non-renal SLE. Most interestingly, our results show that LN patients bear strikingly reduced amounts of circulating PTX3^+^ B cells both in the naïve and memory compartment vs. HD and non-renal SLE. This finding was observed regardless of LN activity, suggesting a characteristic divergence between patient subsets.

Moreover, the current results indicate that selection of PTX3 binding B cells appears to be defective in LN based on the analysis of sole PTX3^+^ B cells and B cell subsets which were able to bind specifically PTX3 molecules using two different dyes blockable by unlabeled antigen. The observation that most circulating PTX3^+^B cells belong to CD27^−^IgD^+^ and to CD27^+^IgD^+^ subsets is not surprising, since PTX3 is a self-antigen without enhanced antigenicity. In this context, lack of detectable PTX3^+^ plasmablasts is consistent with the notion that the B and plasma cell compartments underlie independent regulations ([@B27]--[@B30]), thus at this point it is not possible to establish a direct link between these specific PTX3-B cell subsets and the production of anti-PTX3 antibodies.

Notably, by virtue of its octameric structure, PTX3 is able to bind diverse molecules ([@B12], [@B31], [@B32]) and either living or apoptotic cells ([@B9], [@B13], [@B23]). More recently, the binding of PTX3 to marginal zone (MZ) B cells was described which promoted production of IgM and IgG antibodies, thus suggesting that PTX3 is involved in the regulation of B cell differentiation or potentially in B helper function ([@B24]). So far, however, the binding site of PTX3 other than Fcɤ receptors or Toll-like receptors ([@B23], [@B24]) has not been fully delineated.

It is well-known that regulatory B cell function (both in numbers and functionality) is impaired in SLE ([@B33], [@B34]) and a stable decrease of naïve and memory PTX3^+^B cells in LN patients may hint to an early negative selection or depletion of this specificity in LN. While previous pre-clinical and clinical data showed that anti-PTX3 autoantibodies carry a LN protective potential, it remains to be shown whether this also applies to a potential immunomodulatory function of PTX3^+^ B cells. Alternatively, and not mutually exclusively, the abundance of naïve PTX3^+^ B cells in non-renal SLE may represent polyreactive B cells, which is a common feature of SLE ([@B35], [@B36]), and may give rise to antibody secreting cells *via* an extrafollicular pathway ([@B37]). This would be consistent with the progressive decrease in PTX3^+^B cell subsets from naïve, pre-switch to post-switch memory cells. The current finding of a similar level and distribution of PTX3^+^ B cells in non-renal SLE and HD has some implications. First, their absence in LN suggests that their presence has relevance to protect the kidney. Second, selection processes leading to PTX3^+^ B cell subsets might be intact in SLE as observed for HD. Alternatively and related to the proposed protective function, non-renal SLE patients are able to generate a sufficient amount of PTX3^+^ B cells which could be involved in immune protection being more compromised in LN. As such, the absence of circulating PTX3^+^ B cells in LN may hamper the kidney-protective effect provided by PTX3 specific autoantibodies.

Our study is the first addressing the distribution of autoantigen-specific B cells in lupus, focusing on a molecule of emerging importance, through an original method of selection and verification of autoantigen-specific B cells, which can be thereby identified from peripheral blood of patients or controls with a high level of certainty and in the absence of stimulation.

In summary, this study developed a method to reliably identify PTX3-specific B cells and their subsets. Application of this technology allowed the identification of an abnormal distribution of PTX3^+^ B cells with their absence in LN and a very similar profile among controls and non-renal SLE. To which extent these findings relate to a potential immune regulatory role or protective function of this specificity as well as potential clinical applications in diagnostics or therapeutics remains to be delineated.
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###### 

Representative gating strategy of peripheral B cells according to FSC and SSC characteristics and further identification on their surface expression of CD19, CD20, and subsets according to CD27 surface expression. FSC, forward scatter; SSC, sideward scatter.

###### 

Click here for additional data file.

###### 

Quantification of PTX3 binding among B cells that only bind either PTX3-PE **(A)** or PTX3-Cy5 **(B)** before and after blocking of PTX3 is not significant (Wilcoxon rank test). PTX3, pentraxin 3; Cy5, cyanin 5; PE, phycoerythrin.

###### 

Click here for additional data file.
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